A5027903860- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Lung Cancer Treatments and Mutations
- Chronic Lymphocytic Leukemia Research
- Neutropenia and Cancer Infections
- Acute Lymphoblastic Leukemia research
- Multiple Myeloma Research and Treatments
- Cancer Genomics and Diagnostics
- Polyomavirus and related diseases
- Lymphoma Diagnosis and Treatment
- Advanced Breast Cancer Therapies
- Transplantation: Methods and Outcomes
- Cancer Diagnosis and Treatment
- Hematological disorders and diagnostics
- Cancer Treatment and Pharmacology
- Hemoglobinopathies and Related Disorders
- Bone and Joint Diseases
- Complement system in diseases
- Cancer Immunotherapy and Biomarkers
- Renal Transplantation Outcomes and Treatments
- Platelet Disorders and Treatments
- Palliative Care and End-of-Life Issues
- Lung Cancer Research Studies
- Immune Cell Function and Interaction
Cancer Treatment Centers of America
2016-2021
Eastern Regional Medical Center
2015-2019
Drexel University
2004-2018
Hahnemann University Hospital
2006-2016
Sidney Kimmel Comprehensive Cancer Center
2002
Thomas Jefferson University
2001
University of California, San Francisco
2000
Allegheny College
1998-1999
Johnson University
1998
UPMC Montefiore
1998
We conducted a randomized trial in which we compared high-dose chemotherapy plus hematopoietic stem-cell rescue with prolonged course of monthly conventional-dose women metastatic breast cancer.
Although some reports have found an association between increasing HLA disparity donor and recipient fewer relapses after allogeneic blood or marrow transplantation (BMT), this potential benefit has been offset by more graft-versus-host disease (GVHD) nonrelapse mortality (NRM). However, the type of GVHD prophylaxis might influence balance toxicity relapse. The present study analyzed impact greater on outcomes a specific platform for nonmyeloablative (NMA), HLA-haploidentical...
The TAPUR Study is a phase II basket trial that aims to identify signals of antitumor activity commercially available targeted agents in patients with advanced cancers harboring genomic alterations known be drug targets. Results cohort metastatic breast cancer (mBC) high tumor mutational burden (HTMB) treated pembrolizumab are reported.Patients mBC received standard doses either 2 mg/kg or 200 mg infusions every 3 weeks. Simon's two-stage design was used primary study end point disease...
The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a phase II pragmatic basket trial evaluating antitumor activity of commercially available targeted agents in patients with advanced cancer genomic alterations known to be drug targets. Results cohort non-small-cell lung (NSCLC) CDKN2A treated palbociclib are reported.Eligible were ≥ 18 years old NSCLC, no remaining standard treatment options, measurable disease, Eastern Cooperative Oncology Group performance status 0 2,...
Four patients with chronic inflammatory demyelinating polyneuropathy (CIDP) who were refractory to conventional treatment treated high-dose cyclophosphamide (200 mg/kg over 4 days). All improved in functional status and muscle strength. Nerve conduction studies three of four. Other immunomodulatory medications have been discontinued. High-dose can be given safely CIDP disease persistence after standard therapy may a response that lasts for 3 years results long-term remission.
Abstract We tested the hypothesis that using CXCR4 inhibition to target interaction between tumor cells and microenvironment leads sensitization of apoptosis. Eligibility criteria included multiple myeloma (MM) patients with 1‐5 prior lines therapy. The purposes phase I study were evaluate safety maximal‐tolerated dose (MTD) combination. treatment‐related adverse events response rate combination assessed in II study. A total 58 enrolled median age was 63 years (range, 43‐85), 78% them...
1014 Background: TAPUR is a phase II basket study evaluating the anti-tumor activity of commercially available targeted agents in pts with advanced cancers specific genomic alterations. P an immune checkpoint inhibitor and HTMB emerging predictive biomarker for therapy. Results cohort MBC treated are reported. Methods: Eligible had cancer, no standard treatment options, ECOG PS 0-1, measurable disease acceptable organ function. Genomic testing was performed using tests selected by sites. Pts...
We studied the feasibility, toxicity, and efficacy of a 2-step approach to autologous stem cell transplantation for patients with acute myeloid leukemia in first remission.Step 1 consisted consolidation chemotherapy including cytarabine 2000 mg/m 2 twice daily 4 days concurrent etoposide 40 mg/kg by continuous infusion over d y s .During re c o v e ry from this chemotherapy, peripheral blood cells were collected under granulocyte colonystimulating factor stimulation.Step 2, transplantation,...
Objective To determine if a program to educate referring physicians as the poor outcome of mechanically ventilated bone marrow transplant patients would result in change intensive care unit (ICU) utilization. Design Retrospective chart review. Setting Medical ICU at an urban university hospital. Patients undergoing transplantation interval before (n = 236) vs. after 144) physician education program. Interventions Two separate educational programs were conducted for oncologists and...
Cytotoxic therapy is a cornerstone for patients with severe systemic lupus erythematosus (SLE). High-dose cyclophosphamide, 200 mg/kg, can induce complete remission without the need stem cell rescue in autoimmune illnesses. Here we report on our first four treated SLE this treatment approach. Patients received divided over 4 days. Starting day 10, filgrastim, 5 mg/kg/day, until their absolute neutrophil count (ANC) rose to 10.0 £ 10 9 =l two consecutive Disease activity as evaluated by...
Older patients with Burkitt lymphoma/leukemia (BL) have inferior outcomes. Because cyclophosphamide is highly active in BL and can be dose-escalated without stem-cell rescue, we designed a short, cyclophosphamide-intensive regimen anthracyclines for aged ≥ 30 untreated, non-HIV-associated BL/atypical BL. Two cycles involving 1500 mg/m(2), vincristine, rituximab, prednisone, methotrexate 3 g/m(2), intrathecal cytarabine were delivered 2 weeks apart, followed by intensification high-dose (50...
The initial diagnosis of heparin–induced thrombocytopenia (HIT) is made on clinical grounds because the assays with highest sensitivity (eg, heparin–platelet factor 4 antibody enzyme–linked immunosorbent assay [ELISA]) and specificity serotonin release assay) may not be readily available. utility pretest scoring system, 4Ts, was developed validated by Lo et al in Journal Thrombosis Haemostasis 2006. system looks at degree timing thrombocytopenia, thrombosis, possibility other etiologies....
While half of all patients receiving bone marrow transplantation (BMT) for malignancies and related diseases may achieve prolonged disease-free survival, 2-10% undergoing allogeneic develop bronchiolitis obliterans (BrOb). We have hypothesized that total body irradiation (TBI) which has been used pretreatment influence the subsequent development BrOb in BMT. Since 1976, we treated 104 BMT with non-TBI preconditioning. Of 60 survived were evaluable chronic graft versus host disease (GVHD) 26...